Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d -lysergic acid diethylamide (LSD)

[1]  C. Svarer,et al.  Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels , 2019, Neuropsychopharmacology.

[2]  F. Troxler,et al.  Substitutionen am Ringsystem der Lysergsäure II. Alkylierung. 44. Mitteilung über Mutterkornalkaloide , 1957 .

[3]  V. Auwärter,et al.  Validation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions. , 2019, Journal of pharmaceutical and biomedical analysis.

[4]  Stuart C. Sealfon,et al.  Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.

[5]  A. Halberstadt.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens , 2015, Behavioural Brain Research.

[6]  U. Bredberg,et al.  Kinetics of Methysergide and its Main Metabolite, Methylergometrine, in Man , 1985 .

[7]  S. Corne,et al.  A possible correlation between drug-induced hallucinations in man and a behavioural response in mice , 2004, Psychopharmacologia.

[8]  D. E. Nichols,et al.  Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) , 2018, Psychopharmacology.

[9]  E. sanders-Bush,et al.  Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide. , 1992, Molecular pharmacology.

[10]  F. Vollenweider,et al.  LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation , 2017, Front. Pharmacol..

[11]  D. E. Nichols,et al.  Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ). , 2017, Drug testing and analysis.

[12]  G. Kennett,et al.  Modulation of 5-HT2A receptor-mediated head-twitch behaviour in the rat by 5-HT2C receptor agonists , 2001, Pharmacology Biochemistry and Behavior.

[13]  S. Borgwardt,et al.  Acute LSD effects on response inhibition neural networks , 2017, Psychological Medicine.

[14]  G. Aghajanian,et al.  Persistence of lysergic acid diethylamide in the plasma of human subjects , 1964, Clinical pharmacology and therapeutics.

[15]  S. Dursun,et al.  Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions , 1996, Psychopharmacology.

[16]  D. E. Nichols,et al.  N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues , 2014, ACS chemical neuroscience.

[17]  Niwaguchi Tetsukichi,et al.  Studies on enzymatic dealkylation of D-lysergic acid diethylamide (LSD). , 1974 .

[18]  H Weinstein,et al.  Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. , 1996, Molecular pharmacology.

[19]  U. Bredberg,et al.  Pharmacokinetics of methysergide and its metabolite methylergometrine in the rat. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[20]  D. E. Nichols,et al.  Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). , 2002, Journal of medicinal chemistry.

[21]  T. Inoue,et al.  Studies on the in vitro metabolism of compounds related to lysergic acid diethylamide (LSD). , 1974, Biochemical pharmacology.

[22]  H. Isbell,et al.  Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25) , 2004, Psychopharmacologia.

[23]  J. Henion,et al.  Elucidation of LSD in vitro metabolism by liquid chromatography and capillary electrophoresis coupled with tandem mass spectrometry. , 1996, Journal of analytical toxicology.

[24]  M. Geyer,et al.  Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice , 2011, Journal of psychopharmacology.

[25]  S. J. Chapman,et al.  Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice , 2019, Journal of psychopharmacology.

[26]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[27]  B. Twamley,et al.  Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). , 2018, Drug testing and analysis.

[28]  E. Kast,et al.  Study of Lysergic Acid Diethylamide as an Analgesic Agent , 1964, Anesthesia and analgesia.

[29]  H. Abramson.  Lysergic Acid Diethylamide (LSD-25): XXIX. The Response Index as a Measure of Threshold Activity of Psychotropic Drugs in Man , 1959 .

[30]  T. S. Krebs,et al.  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials , 2012, Journal of psychopharmacology.

[31]  A. Hofmann.  How LSD originated. , 1979, Journal of psychedelic drugs.

[32]  E. Evarts,et al.  THE DISTRIBUTION AND METABOLISM OF LYSERGIC ACID DIETHYLAMIDE , 1957, Annals of the New York Academy of Sciences.

[33]  R. Loncharich,et al.  Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. , 1994, Molecular pharmacology.

[34]  Madeleine Pettersson Bergstrand,et al.  In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures , 2019, Analytical and Bioanalytical Chemistry.

[35]  W. C. Roehrig,et al.  A clinical comparsion of three related hallucinogens , 1960, Psychiatric Quarterly.

[36]  J. Wallach,et al.  Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD). , 2019, Drug testing and analysis.

[37]  D. Morgan,et al.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. , 2012, Drug testing and analysis.

[38]  A. Hofmann,et al.  LSD, my problem child , 1980 .

[39]  J. F. Alonso,et al.  Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans , 2016, European Neuropsychopharmacology.

[40]  F. Vollenweider,et al.  Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation , 2017, Psychopharmacology.

[41]  D. E. Nichols,et al.  Chemistry and Structure-Activity Relationships of Psychedelics. , 2018, Current topics in behavioral neurosciences.

[42]  G. Aghajanian,et al.  d-LSD binding to brain homogenates: possible relationship to serotonin receptors. , 1974, Life sciences.

[43]  C. Tapparelli,et al.  Methylergometrine, an Active Metabolite of Methysergide , 1986, Cephalalgia : an international journal of headache.

[44]  M. Geyer,et al.  Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice , 2016, Neuropharmacology.

[45]  F. Vollenweider,et al.  Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor , 2018, eLife.

[46]  S. Johansen,et al.  Liquid chromatography-tandem mass spectrometry determination of LSD, ISO-LSD, and the main metabolite 2-oxo-3-hydroxy-LSD in forensic samples and application in a forensic case. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[47]  D. Nelson,et al.  N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor. , 1993, European journal of pharmacology.

[48]  J. Wallach,et al.  Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). , 2016, Drug testing and analysis.

[49]  D. Nelson,et al.  Species differences in the pharmacology of the 5-hydroxytryptamine2 receptor: structurally specific differentiation by ergolines and tryptamines. , 1993, The Journal of pharmacology and experimental therapeutics.

[50]  Erich Seifritz,et al.  Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study , 2018, The Journal of Neuroscience.

[51]  M. Geyer,et al.  Effect of Hallucinogens on Unconditioned Behavior. , 2018, Current topics in behavioral neurosciences.

[52]  T. Mieczkowski,et al.  Detection of LSD and metabolite in rat hair and human hair. , 1996, Journal of analytical toxicology.

[53]  R. Glennon,et al.  Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors , 1998, Psychopharmacology.

[54]  R. Smith,et al.  Body fluid levels of lysergide (LSD). , 1985, Forensic science international.

[55]  Stanley Krippner,et al.  LSD: My Problem Child , 1981 .

[56]  M. Geyer,et al.  Characterization of the head-twitch response induced by hallucinogens in mice , 2013, Psychopharmacology.

[57]  B. Hoffman,et al.  Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. , 1992, Molecular pharmacology.

[58]  R. Stevens,et al.  Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.

[59]  Z. Siddik,et al.  The metabolism of lysergic acid DI[14C]ethylamide ([14C]LSD) in the isolated perfused rat liver. , 1979, Biochemical pharmacology.

[60]  F. Vollenweider,et al.  Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music , 2018, Cerebral cortex.

[61]  S. Peroutka.  Pharmacological differentiation of human 5-HT1B and 5-HT1D receptors. , 1994, Biological signals.

[62]  S. Ferrara,et al.  LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor , 2007, International Journal of Legal Medicine.

[63]  Alexander T. Shulgin,et al.  Tihkal : The Continuation , 1997 .

[64]  E. Rothlin.  PHARMACOLOGY OF LYSERGIC ACID DIETHYLAMIDE AND SOME OF ITS RELATED COMPOUNDS , 1957, The Journal of pharmacy and pharmacology.

[65]  T. Passie,et al.  LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects , 2015, Journal of psychopharmacology.

[66]  M. Liechti,et al.  Development and validation of an LC‐MS/MS method to quantify lysergic acid diethylamide (LSD), iso‐LSD, 2‐oxo‐3‐hydroxy‐LSD, and nor‐LSD and identify novel metabolites in plasma samples in a controlled clinical trial , 2018, Journal of clinical laboratory analysis.

[67]  A. Cailleux,et al.  Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[68]  Reid H. J. Olsen,et al.  Structural determinants of 5-HT2B receptor activation and biased agonism , 2018, Nature Structural & Molecular Biology.

[69]  S. Heilig.  The Brotherhood of Eternal Love—From Flower Power to Hippie Mafia: The Story of LSD Counterculture , 2007 .

[70]  S. Brandt,et al.  Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran (“FLY”) and benzodifuran (“DragonFLY”) analogs , 2019, Neuropharmacology.

[71]  D. E. Nichols,et al.  Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). , 2017, Drug testing and analysis.

[72]  Structural determinants of 5-HT2Breceptor activation and biased agonism. , 2018 .

[73]  Z. Siddik,et al.  The fate of lysergic acid di[ 14C]ethlamide ([14-C-A1LSD) in the rat. , 1975, Biochemical Society transactions.

[74]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[75]  K. Klette,et al.  Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[76]  M. Liechti,et al.  Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans , 2015, The international journal of neuropsychopharmacology.

[77]  Z. Siddik,et al.  The fate of lysergic acid DI[14C]ethylamide ([14C]LSD) in the rat, guinea pig and rhesus monkey and of [14C]iso-LSD in rat. , 1979, Biochemical pharmacology.

[78]  A. Enz,et al.  Dopaminergic properties of mesulergine (CU 32-085) and its metabolites , 2005, Journal of Neural Transmission.

[79]  M. Liechti,et al.  Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) , 2015, Neuropharmacology.

[80]  Z. Siddik,et al.  The Fate of Lysergic Acid Di[14C]ethylamide ([14C]LSD) in the Rat , 1975 .

[81]  M. Geyer,et al.  Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response , 2014, Neuropharmacology.

[82]  B. Roth,et al.  Agonist high and low affinity state ratios predict drug intrinsic activity and a revised Ternary complex mechanism at serotonin 5‐HT2A and 5‐HT2C receptors , 2000, Synapse.

[83]  F. Troxler,et al.  Substitutionen am Ringsystem der Lysergsäure I. Substitutionen am Indol‐Stickstoff. 43. Mitteilung über Mutterkornalkaloide , 1957 .

[84]  D. E. Nichols,et al.  Crystal Structure of an LSD-Bound Human Serotonin Receptor , 2017, Cell.

[85]  S. Borgwardt,et al.  Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects , 2017, Translational Psychiatry.

[86]  G. W. Price,et al.  Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. , 2003, Molecular pharmacology.

[87]  F. Vollenweider,et al.  The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation , 2017, Current Biology.

[88]  P. Daley,et al.  Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs , 2018, Neuropharmacology.

[89]  U. Bredberg,et al.  Pharmacokinetics of methysergide and its metabolite methylergometrine in man , 2004, European Journal of Clinical Pharmacology.

[90]  M. Liechti,et al.  Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. , 2017, Drug testing and analysis.

[91]  G. Kennett,et al.  Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. , 2001, Pharmacology, biochemistry, and behavior.

[92]  R. Jones,et al.  Quantification of LSD and N-demethyl-LSD in urine by gas chromatography/resonance electron capture ionization mass spectrometry. , 1988, Analytical chemistry.

[93]  W. Richards,et al.  LSD-assisted psychotherapy with terminal cancer patients. , 1969, Current psychiatric therapies.